Fu Q, Zhu R, Song J, Yang H, Chen X
Tips for the transition Learn what happens when you stop taking a GLP-1 weight-loss drug and how to sustain results
To further explore on- and off-label use of these drugs, Avalere Health evaluated 20182023 commercial (42% population sample), Medicare fee-for-service (FFS) (100%), Medicare Advantage (25%), and Managed Medicaid (69%) pharmacy claims data to identify beneficiaries with a pharmacy drug claim for GLP-1 and/or GIP/GLP-1 RAs
Travel patterns, work schedule, eating windows, family routines, ability to follow a daily versus weekly schedule
doi: 10.1007/s004280000385
In India, even with anticipated price reductions from generic versions, affordability is a challenge